Pharmaceuticals
111, Inc. Enters into First-Ever Strategic Partnership with BeiGene
SHANGHAI, March 17, 2021 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (Nasdaq: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, announced today it has entered into a strategic cooperation agreem...
2021-03-17 18:50
4950
Transcenta Continues to Push the Boundary of Cell Culture Productivity by Achieving > 6 g/L PER Day Volumetric Productivity in Continuous Perfusion Platform
SUZHOU and HANGZHOU, China, March 16, 2021 /PRNewswire/ -- Transcenta, a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced a major breakthrough in its continuous perfusion cell culture p...
2021-03-17 08:00
1793
Market of TCM Lianhua Qingwen Enlarged with Kenya's Approval
SHIJIAZHUANG, China, March 16, 2021 /PRNewswire/ -- In an announcement published by Yiling Pharmaceutical on Tuesday, it is disclosed the enterprise has received the herbal product license for Lianhua Qingwen Capsules from the Pharmacy and Poisons Board of the Ministry of Health ofKenya. Kenya i...
2021-03-16 20:20
2156
Delonix Bioworks Closes $14 Million Series Seed Financing to Accelerate the Development of its Innovative Synthetic Vaccines
SHANGHAI, March 11, 2021 /PRNewswire/ -- Delonix Bioworks Ltd. (Delonix), a biotechnology company dedicated to developing the next generation vaccines with synthetic biology approaches, has recently closed a$14 million Series Seed financing led by Boehringer Ingelheim Venture Fund (BIVF) and IDG ...
2021-03-11 21:21
1936
Kintor Pharmaceutical Announces Results from Investigator-Initiated Brazil Trial Demonstrating 92% Reduction in Mortality in Hospitalized COVID-19 Patients
SUZHOU, China, March 11, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX: 9939), a clinical-stage biotechnology company developing small molecule and biological therapeutics, announced today top-line results from its investigator-initiated Brazil trial evaluating the efficacy of Proxalut...
2021-03-11 14:54
5140
Impact Therapeutics Announced First-Patient-Dose of Wee1 Inhibitor IMP7068 in the U.S.
SHANGHAI, March 10, 2021 /PRNewswire/ -- Impact Therapeutics announced today that the first patient was recently dosed in the first-in-human Phase 1 clinical study of Wee1 Inhibitor IMP7068 inthe United States. This is a Phase 1, open-label, multi-center, dose escalation and expansion study to e...
2021-03-10 21:14
1912
Arctic Vision Announces Completion of Over US$100 Million Series B Financing to Accelerate Portfolio Expansion, Clinical Development and Commercialization
SHANGHAI, March 9, 2021 /PRNewswire/ -- Arctic Vision, a China-based clinical-stage ophthalmology company focused on developing innovative therapies for pan-ocular diseases, today announced the completion of overUS$100 million Series B financing. The Series B round was led by Loyal Valley Capital...
2021-03-10 08:00
2312
Alphamab Received U.S. FDA IND Clearance to Initiate A Phase II Pivotal Clinical Trial of KN046 (KN046-205,ENREACH-Thymic) in the U.S.
SUZHOU, China, March 9, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug application (IND) to initiate an open label, multi-center phase II pivotal clinical study (clinical trial ...
2021-03-09 20:00
3902
Nippon Express (Malaysia) Obtains GDP Certification for Domestic Transport Services
TOKYO, March 9, 2021 /PRNewswire/ -- Nippon Express (Malaysia) Sdn, Bhd. (hereinafter, "NE Malaysia"), a local subsidiary of Nippon Express Co., Ltd. based inTokyo, has obtained Good Distribution Practice (GDP) certification effectiveThursday, January 14, 2021 for its Kuala Lumpur International A...
2021-03-09 15:00
1877
Yangtze River Pharmaceutical (Group) Co., Ltd. Won the 2021 EFQM Global Award
TAIZHOU, China, March 8, 2021 /PRNewswire/ -- At 19:20 on March 4, 2021 (Beijing time), the results of the 2021 EFQM Global Award were announced. Yangtze River Pharmaceutical (Group) Co., Ltd. fromChina was on the list, which represents that its quality management level has been aligned with that...
2021-03-09 11:19
1810
Winhealth Pharma and Merz Collaborate on Hepa-Merz® to benefit patients with liver disease in China
HANG ZHOU, China, March 8, 2021 /PRNewswire/ -- On Feb. 26th, 2021, Hongkong Winhealth Pharma Group Co., Ltd (hereinafter referred to as "Winhealth Pharma") signed a strategic cooperation agreement with Merz Pharmaceuticals GmbH (hereinafter referred to as "Merz"). The strategic cooperation betwe...
2021-03-09 10:00
3615
CMAB Biopharma Congratulates Partner Junshi Biosciences on NMPA Acceptance of Application for a Clinical Trial of its PD-1/TGF-β Bifunctional Fusion Protein
SUZHOU, China, March 7, 2021 /PRNewswire/ -- Recently, CMAB Biopharma (Suzhou) Inc's ("CMAB") partner Shanghai Junshi Biosciences Co., Ltd. ("Junshi Biosciences") (HK: 1877; SH: 688180), announced that a clinical trial application for its PD-1/TGF-β bifunctional fusion protein JS201 injection (J...
2021-03-08 11:41
1999
Adlai Nortye Announces Formation of its New Scientific Advisory Board
HANGZHOU, China, March 7, 2021 /PRNewswire/ -- Adlai Nortye, a global clinical-stage biopharmaceutical company, today announced the formation of its new Scientific Advisory Board (SAB) comprised of five internationally renowned experts. The SAB includesRonald M. Evans, PhD (Member of the US Natio...
2021-03-08 09:00
1975
Proxalutamide Phase III Clinical Trial for the Treatment of COVID-19 Patients Approved by FDA
SUZHOU, China, March 5, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX: 9939) is pleased to announce that the Investigational New Drug (IND) application of the phase III clinical trial of Proxalutamide's treatment of male COVID-19 outpatients has been approved by the United States Food ...
2021-03-05 21:00
8122
ABclonal Biotechnology Acquires Yurogen Biosystems to Better Serve Diagnostic and Pharmaceutical Researchers Worldwide
BOSTON, March 5, 2021 /PRNewswire/ -- ABclonal Biotechnology Co., Ltd., a global life science tools and services provider, acquires Yurogen Biosystems LLC, a contract research organization dedicated to monoclonal antibody discovery using single-B-cell-based SMabTM platform, to better serve resea...
2021-03-05 20:00
3092
Mayne Pharma launches another generic oral contraceptive
ADELAIDE, Australia, March 4, 2021 /PRNewswire/ -- Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the commercial launch of a generic version of ORTHO-CEPT® (desogestrel and ethinyl estradiol 0.15 mg / 0.03 mg) tablets to customers in the US. This is the fourth oral contraceptive la...
2021-03-05 05:34
5228
Foresee Pharmaceuticals Enters Exclusive License Agreement with Intas Pharmaceuticals for Commercialization in the United States
TAIPEI, March 4, 2021 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO) ("Foresee") announced today that it has entered into an exclusive license agreement with Intas Pharmaceuticals ("Intas") for the US commercialization of Foresee's novel FP-001 program, Leuprolide Mesylate Injectable Suspensi...
2021-03-04 23:00
3599
Yuyu Pharma Publishes History for 80th Anniversary
SEOUL, South Korea, March 3, 2021 /PRNewswire/ -- Yuyu Pharma (KRX: 000220, CEO Robert Wonsang Yu), in anticipation of the 80th anniversary of its establishment onFebruary 28th, 2021, published its history of challenges and changes over the past 80 years. The history is told in storytelling forma...
2021-03-03 22:00
2428
I-Mab to Report Financial Results for the Full Year 2020 and Provide Corporate Update on March 29, 2021
SHANGHAI and GAITHERSBURG, Md., March 3, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that it will report financial results for the full year ...
2021-03-03 21:00
5596
SciClone Pharmaceuticals Officially Listed on the Main Board of the Hong Kong Stock Exchange
SHANGHAI, March 3, 2021 /PRNewswire/ -- SciClone Pharmaceuticals (Holdings) Limited ("SciClone Pharmaceuticals" or "SciClone") was officially listed today on the Main Board of The Stock Exchange of Hong Kong Limited ("Hong Kong Stock Exchange" or "HKEx") under stock code: 6600. In the initial of...
2021-03-03 16:43
8034
Week's Top Stories
Most Reposted
Nine Years of Impact: JULO Disburses USD 1.7 Billion in Digital Financing Across Indonesia
[Picked up by 297 media titles]
2025-12-23 14:23
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
[Picked up by 277 media titles]
2025-12-26 12:55Fijian and Chinese Scholars Gather to Discuss Bilateral Friendship and the Outlook for APEC 2026
[Picked up by 264 media titles]
2025-12-22 15:56
"Nihao China" App Launches as an All-in-One Solution for International Visitors
[Picked up by 253 media titles]
2025-12-24 17:54Sobot Shines in G2 Winter 2026: A New Benchmark in AI Customer Service
[Picked up by 252 media titles]
2025-12-24 10:00